Urogen Pharma Ltd
Follow $URGN
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $URGN by emailVeridion Score
BETALOW CONF · 5 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is URGN moving today?
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
URGN overview
Related filings and maps
Congress activity in URGN
No receipt-qualified Congressional disclosure is present for URGN in the cached public ledger.
URGN contract awards, year to date.
Public federal awards linked to this ticker.
URGN lobbying filings, year to date.
Registered lobbying filings matched to Urogen Pharma Ltd.
BGR GOVERNMENT AFFAIRS
BGR GOVERNMENT AFFAIRS
BGR GOVERNMENT AFFAIRS